Histone Methyltransferases as Therapeutic Targets for Kidney Diseases

Emerging evidence has demonstrated that epigenetic regulation plays a vital role in gene expression under normal and pathological conditions. Alterations in the expression and activation of histone methyltransferases (HMTs) have been reported in preclinical models of multiple kidney diseases, includ...

Full description

Bibliographic Details
Main Authors: Chao Yu, Shougang Zhuang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01393/full
id doaj-b193bacb8f0647e59f81409f487b7e15
record_format Article
spelling doaj-b193bacb8f0647e59f81409f487b7e152020-11-25T01:44:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-12-011010.3389/fphar.2019.01393470433Histone Methyltransferases as Therapeutic Targets for Kidney DiseasesChao Yu0Shougang Zhuang1Shougang Zhuang2Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, United StatesEmerging evidence has demonstrated that epigenetic regulation plays a vital role in gene expression under normal and pathological conditions. Alterations in the expression and activation of histone methyltransferases (HMTs) have been reported in preclinical models of multiple kidney diseases, including acute kidney injury, chronic kidney disease, diabetic nephropathy, polycystic kidney disease, and renal cell carcinoma. Pharmacological inhibition of these enzymes has shown promise in preclinical models of those renal diseases. In this review, we summarize recent knowledge regarding expression and activation of various HMTs and their functional roles in some kidney diseases. The preclinical activity of currently available HMT inhibitors and the mechanisms of their actions are highlighted.https://www.frontiersin.org/article/10.3389/fphar.2019.01393/fullchronic kidney diseasesepigenetic regulationshistone modificationhistone methyltransferasesexpression
collection DOAJ
language English
format Article
sources DOAJ
author Chao Yu
Shougang Zhuang
Shougang Zhuang
spellingShingle Chao Yu
Shougang Zhuang
Shougang Zhuang
Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
Frontiers in Pharmacology
chronic kidney diseases
epigenetic regulations
histone modification
histone methyltransferases
expression
author_facet Chao Yu
Shougang Zhuang
Shougang Zhuang
author_sort Chao Yu
title Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
title_short Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
title_full Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
title_fullStr Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
title_full_unstemmed Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
title_sort histone methyltransferases as therapeutic targets for kidney diseases
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2019-12-01
description Emerging evidence has demonstrated that epigenetic regulation plays a vital role in gene expression under normal and pathological conditions. Alterations in the expression and activation of histone methyltransferases (HMTs) have been reported in preclinical models of multiple kidney diseases, including acute kidney injury, chronic kidney disease, diabetic nephropathy, polycystic kidney disease, and renal cell carcinoma. Pharmacological inhibition of these enzymes has shown promise in preclinical models of those renal diseases. In this review, we summarize recent knowledge regarding expression and activation of various HMTs and their functional roles in some kidney diseases. The preclinical activity of currently available HMT inhibitors and the mechanisms of their actions are highlighted.
topic chronic kidney diseases
epigenetic regulations
histone modification
histone methyltransferases
expression
url https://www.frontiersin.org/article/10.3389/fphar.2019.01393/full
work_keys_str_mv AT chaoyu histonemethyltransferasesastherapeutictargetsforkidneydiseases
AT shougangzhuang histonemethyltransferasesastherapeutictargetsforkidneydiseases
AT shougangzhuang histonemethyltransferasesastherapeutictargetsforkidneydiseases
_version_ 1725027161048350720